Anti-Mouse Delta-like protein 4 (DLL4) - Purified <i>in vivo </i>PLATINUM™ Functional Grade (D292-GRP)

The Notch pathway is an intercellular signaling mechanism that controls cell fate and differentiation during embryonic and postnatal development1,2. The pathway is highly conserved across species. Four mammalian Notch receptors (Notch 1-4) have been identified and can be activated by their ligands Jagged1, Jagged2, DLL1, DLL3, or DLL4. These ligands are transmembrane proteins that contain a Delta/Serrate/Lag-2 extracellular domain that is used for interactions with the Notch receptors2. Receptor-ligand engagement triggers cleavage of the Notch receptor extracellular domain, leading to the release of the Notch intracellular domain which travels to the nucleus and affects target gene expression. Dysregulation of Notch signaling affects inflammation2 as well as tumorigenesis and cancer growth1,3. DLL4 is specifically involved in angiogenesis4 and retinal progenitor proliferation5. HMD4-2 was generated by immunizing an Armenian hamster with recombinant mouse DLL4 and screening for antibodies that block rat Notch1-Fc binding to CHO cells expressing mouse DLL46,7. HMD4-2 blocks Notch1-Fc binding to DLL4-expressing CHO cells in a dose- dependent manner7. HMD4-2 does not cross-react with mouse DLL1, Jagged1, Jagged2, or human DLL4. DLL4 blockade suppresses solid tumor growth in mouse.